Abstract
To the Editor. —Itraconazole, recently approved for the treatment of blastomycosis and histoplasmosis (Sporanox, Janssen Pharmaceutica, Piscataway, NJ), is a triazole antifungal with important activity against other fungal pathogens, including Candida albicans and Cryptococcus neoformans . 1 Reports of significant drug interactions with concurrent itraconazole therapy include increased cyclosporine and digoxin concentrations and reduced itraconazole serum concentrations when administered with rifampin, phenytoin, antacids, and histamine-2 antagonists. 1-3 We report a case suggestive of reduced itraconazole absorption when taken with didanosine. Report of a Case. —In October 1992, a 35-year-old Hispanic man presented to our clinic with primary complaints of headache, nausea, and vomiting for approximately 2 weeks. The patient's medical history was significant for the acquired immunodeficiency syndrome and cryptococcal meningitis. On successful completion of primary therapy for cryptococcal meningitis in May 1992 (cerebrospinal fluid lecithin cholesterol acyltransferase, 1:20), he was enrolled in a blinded evaluation of either fluconazole (400 mg/d)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
